Exosomal miRNA profiling before and after surgery revealed potential diagnostic and prognostic markers for lung adenocarcinoma

Xue, Xinying; Wang, Chen; Xue, Zhiqiang; Wen, Jiaxin; Han, Jun; Ma, Xidong; Zang, Xuelei; Deng, Hui; Guo, Rui; Asuquo, Idorenyin Polycarp; Chong, Qin; Wang, Haijiao; Gao, Quansheng; Liu, Sanhong; Wang, Jianxin

doi:10.1093/abbs/gmz164

Cited by 27 publications

(25 citation statements)

References 31 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…miRNA sequencing was performed using plasma exosomes representing all three groups. In total, 159 miRNAs were found to be significantly dysregulated in LA-pre samples vs. healthy volunteers; 24 miRNAs were significantly dysregulated in LA-pre-vs. post-operation; and a further 12 miRNAs showed the same trend, e.g., miR-342-5p (consistent with above study (Xue et al, 2020), miR-574-5p, and miR-222-3p (Han et al, 2020). The AUC values of miR-342-5p and miR-574-5p were both greater than 0.7 (Han et al, 2020).…”

Section: Diagnostic Valuesupporting

confidence: 85%

“…Plasma exosomal miR-23b-3p, miR-10b-5p, and miR-21-5p were independently associated with poor overall survival (Liu et al, 2017). Kaplan-Meier survival analysis showed that higher expression of miR-151a-5p, miR-10b-5p, miR-192-5p, miR-106b-3p, and miR-484 was associated with a lower survival rate (Xue et al, 2020), implicating them as prognostic biomarker candidates. Survival analysis showed that NSCLC patients with high serum exosomal miR-1246 had shorter OS and DFS than patients with low serum exosomal miR-1246 (Huang and Qu, 2020).…”

Section: Prognostic Valuementioning

confidence: 95%

“…Several new studies on LA have recently been published. A recent study using exosomal miRNA profiling showed that 38 miRNAs were significantly upregulated in plasma exosomes of LA compared with a healthy control, e.g., miR-96-5p (about 800fold), miR-151a-5p, miR-342-3p, miR-374a-5p, miR-126-5p, miR-16-2-3p, and miR-106b-3p (Xue et al, 2020), whereas 37 downregulated miRNAs were detected. miR-129-5p and miR-9-3p were highly enriched in the exosomes of the healthy control but undetectable in the plasma exosomes of LA patients.…”

Section: Diagnostic Valuementioning

confidence: 98%

See 2 more Smart Citations

Extracellular Vesicle-Associated miRNAs as a Biomarker for Lung Cancer in Liquid Biopsy

Park

Chang

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

Extracellular vesicles are cell-derived membranous vesicles that are secreted into biofluids. Emerging evidence suggests that EVs play an essential role in the pathogenesis of many diseases by transferring proteins, genetic material, and small signaling molecules between cells. Among these molecules, microRNAs (miRNAs), a type of small noncoding RNA, are one of the most important signals and are involved in various biological processes. Lung cancer is one of the leading causes of cancer-related deaths worldwide. Early diagnosis of lung cancer may help to reduce mortality and increase the 5 years survival rate and thereby reduce the associated socioeconomic burden. In the past, EV-miRNAs have been recognized as biomarkers of several cancers to assist in diagnosis or prognosis. In this review, we discuss recent findings and clinical practice for EV-miRNAs of lung cancer in several biofluids, including blood, bronchoalveolar lavage fluid (BALF), and pleural lavage.

show abstract

Section: Diagnostic Valuesupporting

confidence: 85%

Section: Prognostic Valuementioning

confidence: 95%

Section: Diagnostic Valuementioning

confidence: 98%

See 1 more Smart Citation

Extracellular Vesicle-Associated miRNAs as a Biomarker for Lung Cancer in Liquid Biopsy

Park

Chang

et al. 2021

Front. Mol. Biosci.

View full text Add to dashboard Cite

show abstract

“…In a study by Xue et al, exosomal miRNA plasma profiling was performed from six lung adenocarcinoma patients before and after surgery. miR-484 was found significantly increased in plasma of lung adenocarcinoma patients compared to controls, but it decreased post-surgery [78].…”

Section: Mirnas Alterations and Cancermentioning

confidence: 86%

Measurements Methods for the Development of MicroRNA-Based Tests for Cancer Diagnosis

Precazzini

Detassis²,

Imperatori

et al. 2021

IJMS

View full text Add to dashboard Cite

Studies investigating microRNAs as potential biomarkers for cancer, immune-related diseases, or cardiac pathogenic diseases, among others, have exponentially increased in the last years. In particular, altered expression of specific miRNAs correlates with the occurrence of several diseases, making these molecules potential molecular tools for non-invasive diagnosis, prognosis, and response to therapy. Nonetheless, microRNAs are not in clinical use yet, due to inconsistencies in the literature regarding the specific miRNAs identified as biomarkers for a specific disease, which in turn can be attributed to several reasons, including lack of assay standardization and reproducibility. Technological limitations in circulating microRNAs measurement have been, to date, the biggest challenge for using these molecules in clinical settings. In this review we will discuss pre-analytical, analytical, and post-analytical challenges to address the potential technical biases and patient-related parameters that can have an influence and should be improved to translate miRNA biomarkers to the clinical stage. Moreover, we will describe the currently available methods for circulating miRNA expression profiling and measurement, underlining their advantages and potential pitfalls.

show abstract

“…If NSCLC patients can be found and diagnosed in early stage, there will be more treatment options to ensure better overall survival. Liquid biopsy is a currently promising technology for early diagnosis of NSCLC based on blood contents, such as circulating tumor cells [5], circulating tumor DNA [6], and exosomes [7].…”

Section: Introductionmentioning

confidence: 99%

Tumor-derived exosomal miR-155-5p and miR-658 in serum as diagnostic biomarkers for early-stage non-small cell lung cancer

Zhang¹,

Song²,

Xie

et al. 2020

Preprint

View full text Add to dashboard Cite

Abstract Background Exosomal microRNAs (ExmiRNAs) provided a non-invasive and ideal method for cancer diagnosis. However, few studies identified the role of specific serum ExmiRNAs profiles in early non-small cell lung cancer (NSCLC) diagnosis, especially for 0 and I stage. Herein, the present study was designed to validate the novel serum ExmiRNAs as diagnostic biomarkers for early-stage NSCLC. Methods Serum exosomes were collected from the healthy donors and NSCLC patients by ultracentrifugation, and characterized with qNano, TEM, and western immunoblotting. Exosomal RNAs were subjected to miRNA array for evaluating the expression levels of miRNAs. Partly differently expressed serum exosomal miRNAs were verified by large-scale samples from 312 healthy donors and 318 NSCLC patients. Results The expression levels of ExmiR-155-5p and ExmiR-658 were significantly down-regulated in NSCLC patients compared to healthy donors (p < 0.0001 and p < 0.0001, respectively), and they could differentiate NSCLC patients from healthy donors with area under the ROC curve (AUC) of 0.716 and 0.728, respectively. In addition, combination of ExmiR-155-5p and ExmiR-658 could improve the diagnostic capacity with AUC value of 0.781. Moreover, ExmiR-155-5p and ExmiR-658 could differentiate early-stage NSCLC patients (0 and I stage) from healthy donors with AUC values of 0.668 and 0.735, respectively, combination could improve the diagnostic capacity with AUC value of 0.759. Specifically, the expression of ExmiR-155-5p was significantly decreased in patients with lymph node metastasis and distant metastasis (p = 0.0018 and p = 0.0077, respectively). Conclusions Our results identified that serum ExmiR-155-5p and ExmiR-658 were promising diagnostic biomarkers for early-stage NSCLC, and combination of them could improve the diagnostic capacity.

show abstract

Exosomal miRNA profiling before and after surgery revealed potential diagnostic and prognostic markers for lung adenocarcinoma

Cited by 27 publications

References 31 publications

Extracellular Vesicle-Associated miRNAs as a Biomarker for Lung Cancer in Liquid Biopsy

Extracellular Vesicle-Associated miRNAs as a Biomarker for Lung Cancer in Liquid Biopsy

Measurements Methods for the Development of MicroRNA-Based Tests for Cancer Diagnosis

Tumor-derived exosomal miR-155-5p and miR-658 in serum as diagnostic biomarkers for early-stage non-small cell lung cancer

Contact Info

Product

Resources

About